NCT03824080 - Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 20, 2018

Primary Completion Date

July 13, 2020

Study Completion Date

June 8, 2021

Conditions

Acute Myeloid LeukemiaHigh-risk Myelodysplastic SyndromeLow-risk Myelodysplastic Syndrome

Interventions

DRUG

Bemcentinib

"Bemcentinib will be self-administered orally (fasted) at a dose mentioned above for a total of at least 4 cycles daily.~Responding patients (defined as at least stable disease) are eligible for up to 5 additional cycles according to the maintenance daily dosing of 2 x 1 capsules of 100 mg for each 28 days cycle (up to 9 cycles in total)."

Trial Locations (8)

44093

CHU Hôtel Dieu Service d'Hématologie Clinique, Nantes

75010

Service d'Hématologie Séniors, Paris

06200

Hôpital Archet 1 Service d'Hématologie Clinique, Nice

01307

Universitätsklinikum Dresden, Dresden

Unknown

Marien Hospital GmbH, Düsseldorf

Technische Universität München, Klinikum rechts der Isar, Munich

04103

Universitätsklinikum Leipzig, Leipzig

1081 HV

VU University Medical Center, Amsterdam